Publications Search - Abstract View
||Apolipoprotein E genotypes and the risk of Parkinson disease.
||Gao J, Huang X, Park Y, Liu R, Hollenbeck A, Schatzkin A, Mailman RB, Chen H
||We examined apolipoprotein E (ApoE) genotypes in relation to Parkinson's disease (PD) among 786 cases and 1537 controls, all non-Hispanic Caucasians. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from multivariate logistic regression models, adjusting for year of birth, sex, smoking status, daily caffeine intake, and family history of PD. Compared with participants with ApoE Îµ33, Îµ4 carriers (Îµ34/Îµ44) had significantly lower odds for having PD (OR, 0.75; 95% CI, 0.59-0.94; p = 0.01), whereas Îµ2 carriers (Îµ23/Îµ22) did not (OR, 0.95; 95% CI, 0.73-1.24; p = 0.71). Subgroup analyses showed similar results. In addition, we conducted a meta-analysis which confirmed our primary findings (Îµ34/Îµ44 vs. Îµ33: OR, 0.90; 95% CI, 0.81-0.99; p = 0.024 and Îµ23/Îµ22 vs. Îµ33: OR, 1.10; 95% CI, 0.97-1.23; p = 0.13). In PD patients, the prevalence of dementia appeared to be higher among Îµ4 carriers (compared with Îµ33: OR, 1.59; 95% CI, 0.98-2.58; p = 0.06), but lower among Îµ2 carriers (OR, 0.75; 95% CI, 0.40-1.42; p = 0.38), although neither test was statistically significant. Our study suggested that the ApoE Îµ4 allele may be associated with a lower PD risk among non-Hispanic Caucasians.